ArticleInternational journal of pharmaceutics: X2026
PLGA based formulations with poly(2-oxazoline)s for controlled dexamethasone release from thin extrudates.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PLGA is a landmark in polymer-based drug delivery, due to its biocompatibility, biodegradability and great mechanical strength. However, its high mechanical resistance tends to be unfavorable for implantation, as it creates sharp edges upon rupture, which can cause damage to the patient. Adding polyethylene glycol (PEG) as plasticizer reduces stiffness in PLGA blends, however with significant drawbacks due to deformation upon implantation. This motivates our evaluation of poly (2-alkyl-oxazoline)s (POx) as an alternative plasticizer for PLGA, probing its mechanical properties and the release behavior of dexamethasone (Dex) from POx/PLGA-based blends. Poly(2-oxazoline)s with defined chain length bearing different alkyl side chains were synthesized using a microwave assisted living polymerization, and characterized using gel permeation chromatography (GPC) and matrix assisted laser desorption ionization time of flight (MALDI-ToF) mass spectrometry. To achieve a homogeneous distribution of the POx inside the PLGA-polymer blend, polymer powders were cryo-milled and subsequently extruded, creating thin filaments as possible candidates for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.